Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer

Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance. In this study, we show that gefitinib significantly induces downregulation of Sterol Regulator Element Bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chuncao, Zhang, Lei, Wang, Daifei, Jiang, Shiqin, Cao, Di, Zhao, Zhongxiang, Huang, Min, Jin, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590692/
https://www.ncbi.nlm.nih.gov/pubmed/34775471
http://dx.doi.org/10.1038/s41420-021-00744-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590692/
https://www.ncbi.nlm.nih.gov/pubmed/34775471
http://dx.doi.org/10.1038/s41420-021-00744-1

Ejemplares similares